Academic Journal
Diuretic and Anti-hyperuricemic Effects of Geranyl Acetate in Rats.
| Τίτλος: | Diuretic and Anti-hyperuricemic Effects of Geranyl Acetate in Rats. |
|---|---|
| Συγγραφείς: | Shah SN; Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan., Younis W; Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan.; Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, , New York University Grossman School of Medicine, New York, USA., Junior AG; Laboratory of Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Brazil., Manzoor W; Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan., Malik MNH; Faculty of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan., Mushtaq MN; Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan., Munir MU; Australian Institute for Bioengineering & Nanotechnology, The University of Queensland, Brisbane, Australia., Bashir A; Riphah Institute of Pharmaceutical Sciences, Riphah International Univeristy, Lahore, Pakistan., Bibi S; Department of Biosciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan., Talha M; Department of Pharmacology, Faculty of Pharmacy, The University of Lahore, Lahore, Pakistan., Dos Reis Livero FA; Laboratory of Cardiometabolic Pharmacology, Federal University of Paraná, Curitiba, Brazil.; Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil. |
| Πηγή: | Current medicinal chemistry [Curr Med Chem] 2026; Vol. 33 (8), pp. 1551-1567. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9440157 Publication Model: Print Cited Medium: Internet ISSN: 1875-533X (Electronic) Linking ISSN: 09298673 NLM ISO Abbreviation: Curr Med Chem Subsets: MEDLINE |
| Imprint Name(s): | Publication: Saif Zone, Sharjah, U.A.E. : Bentham Science Publishers Original Publication: Schiphol, The Netherlands : Bentham Science Publishers |
| Ιατρικοί όροι (MeSH): | Hyperuricemia*/drug therapy , Hyperuricemia*/metabolism , Diuretics*/pharmacology , Diuretics*/chemistry , Diuretics*/therapeutic use , Acetates*/pharmacology , Acetates*/chemistry , Acetates*/therapeutic use, Xanthine Oxidase/antagonists & inhibitors ; Xanthine Oxidase/metabolism ; Acetylcholinesterase/metabolism ; Urease/metabolism ; Urease/antagonists & inhibitors ; Animals ; Male ; Rats, Wistar ; Molecular Docking Simulation ; Rats |
| Περίληψη: | Background: Geranyl acetate, a compound found in plant oils, has been studied for its potential effects on renal and cardiovascular ailments. Objective: This study aimed to investigate the diuretic and anti-hyperuricemic properties of geranyl acetate in male Wistar rats using a hyperuricemia-induced rat model. Methods: Molecular docking studies were conducted to assess geranyl acetate's interactions with various targets. In vitro studies were performed to evaluate its scavenging ability and inhibition of xanthine oxidase, urease, and acetylcholinesterase. Subsequently, we administered different doses of geranyl acetate (25, 50, and 100 mg/kg) and a reference drug (furosemide) to the rats to assess their acute and repeated dose diuretic effects over seven days. To understand the diuretic mechanism, we used inhibitors, such as LNAME, indomethacin, and atropine, prior to administering geranyl acetate. We also tested the anti-hyperuricemic potential of geranyl acetate on hyperuricemic rats. Results: Molecular docking suggested strong binding between geranyl acetate and nitric oxide synthase. In vitro studies showed significant free radical scavenging activity and and inhibition of acetylcholinesterase, xanthine oxidase, and urease. The 100 mg/kg dose exhibited the most promising diuretic effects, with nitric oxide appearing to influence its action. Uric acid excretion increased at this dose, resembling allopurinol effects. Conclusion: Geranyl acetate has demonstrated significant diuretic and anti-hyperuricemic effects, likely influenced by nitric oxide release and inhibition of enzymes, like xanthine oxidase and urease. The findings have suggested potential benefits for individuals with kidney ailments, hypertension, and gout. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| References: | Kovesdy C.P.; Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl 2022,12(1),7-11. (PMID: 10.1016/j.kisu.2021.11.00335529086) Kjeldsen S.E.; Hypertension and cardiovascular risk: General aspects. Pharmacol Res 2018,129,95-99. (PMID: 10.1016/j.phrs.2017.11.00329127059) Levin A.; Chaudhry M.R.; Djurdjev O.; Beaulieu M.; Komenda P.; Diabetes, kidney disease and cardiovascular disease patients. Assessing care of complex patients using outpatient testing and visits: Additional metrics by which to evaluate health care system functioning. Nephrol Dial Transplant 2009,24(9),2714-2720. (PMID: 10.1093/ndt/gfp18019395415) Henry R.M.A.; Kostense P.J.; Bos G.; Dekker J.M.; Nijpels G.; Heine R.J.; Bouter L.M.; Stehouwer C.D.A.; Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002,62(4),1402-1407. (PMID: 10.1111/j.1523-1755.2002.kid571.x12234312) Nishizawa H.; Maeda N.; Shimomura I.; Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res 2022,45(4),635-640. (PMID: 10.1038/s41440-021-00840-w35046512) Ali N.; Perveen R.; Rahman S.; Mahmood S.; Rahman S.; Islam S.; Haque T.; Sumon A.H.; Kathak R.R.; Molla N.H.; Islam F.; Mohanto N.C.; Nurunnabi S.M.; Ahmed S.; Rahman M.; Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. PLoS One 2018,13(11),e0206850. (PMID: 10.1371/journal.pone.020685030383816) Kozioł A.; Stryjewska A.; Librowski T.; Sałat K.; Gaweł M.; Moniczewski A.; Lochyński S.; An overview of the pharmacological properties and potential applications of natural monoterpenes. Mini Rev Med Chem 2015,14(14),1156-1168. (PMID: 10.2174/138955751466614112714582025429661) Gonçalves M.J.; Cruz M.T.; Tavares A.C.; Cavaleiro C.; Lopes M.C.; Canhoto J.; Salgueiro L.; Composition and biological activity of the essential oil from Thapsia minor, a new source of geranyl acetate. Ind Crops Prod 2012,35(1),166-171. (PMID: 10.1016/j.indcrop.2011.06.030) Qi F.; Yan Q.; Zheng Z.; Liu J.; Chen Y.; Zhang G.; Geraniol and geranyl acetate induce potent anticancer effects in colon cancer Colo-205 cells by inducing apoptosis, DNA damage and cell cycle arrest. J BUON 2018,23(2),346-352. (PMID: 29745075) Quintans-Júnior L.; Moreira J.C.F.; Pasquali M.A.B.; Rabie S.M.S.; Pires A.S.; Schröder R.; Rabelo T.K.; Santos J.P.A.; Lima P.S.S.; Cavalcanti S.C.H.; Araújo A.A.S.; Quintans J.S.S.; Gelain D.P.; Antinociceptive activity and redox profile of the monoterpenes. ISRN Toxicol 2013,2013,1-11. (PMID: 10.1155/2013/45953023724298) Moretti M.D.L.; Peana A.T.; Satta M.; A study on anti-inflammatory and peripheral analgesic action of Salvia sclarea oil and its main components. J Essent Oil Res 1997,9(2),199-204. (PMID: 10.1080/10412905.1997.9699459) Plata-Rueda A.; Martínez L.C.; Rolim G.S.; Coelho R.P.; Santos M.H.; Tavares W.S.; Zanuncio J.C.; Serrão J.E.; Insecticidal and repellent activities of Cymbopogon citratus (Poaceae) essential oil and its terpenoids (citral and geranyl acetate) against Ulomoides dermestoides. Crop Prot 2020,137,105299. (PMID: 10.1016/j.cropro.2020.105299) Shah G.; Shri R.; Panchal V.; Sharma N.; Singh B.; Mann A.S.; Scientific basis for the therapeutic use of Cymbopogon citratus, stapf (Lemon grass). J Adv Pharm Technol Res 2011,2(1),3-8. (PMID: 10.4103/2231-4040.7979622171285) Sahib N.G.; Anwar F.; Gilani A.H.; Hamid A.A.; Saari N.; Alkharfy K.M.; Coriander (Coriandrum sativum L.): A potential source of high-value components for functional foods and nutraceuticals-a review. Phytother Res 2013,27(10),1439-1456. (PMID: 10.1002/ptr.489723281145) Food Chemicals Codex. Committee on food protection national research council. national academy os sciences, Washington D.C. Available From: https://law.resource.org/pub/us/cfr/ibr/004/nas.food.1972.pdf1972. National Toxicology Program. NTP carcinogenesis studies of food grade geranyl acetate (71% geranyl acetate, 29% citronellyl acetate) (CAS No. 105-87-3) in F344/N rats and B6C3F1 mice (gavage study). Natl Toxicol Program Tech Rep Ser 1987,252,1-162. (PMID: 12748693) Kim S.; Thiessen P.A.; Bolton E.E.; Chen J.; Fu G.; Gindulyte A.; Han L.; He J.; He S.; Shoemaker B.A.; Wang J.; Yu B.; Zhang J.; Bryant S.H.; PubChem substance and compound databases. Nucleic Acids Res 2016,44(D1),D1202-D1213. (PMID: 10.1093/nar/gkv95126400175) Sussman J.L.; Lin D.; Jiang J.; Manning N.O.; Prilusky J.; Ritter O.; Abola E.E.; Protein Data Bank (PDB): Database of three-dimensional structural information of biological macromolecules. Acta Crystallogr D Biol Crystallogr 1998,54(6),1078-1084. (PMID: 10.1107/S090744499800937810089483) Holden J.K.; Lim N.; Poulos T.L.; Identification of redox partners and development of a novel chimeric bacterial nitric oxide synthase for structure activity analyses. J Biol Chem 2014,289(42),29437-29445. (PMID: 10.1074/jbc.M114.59516525194416) Toyoda Y.; Morimoto K.; Suno R.; Horita S.; Yamashita K.; Hirata K.; Sekiguchi Y.; Yasuda S.; Shiroishi M.; Shimizu T.; Urushibata Y.; Kajiwara Y.; Inazumi T.; Hotta Y.; Asada H.; Nakane T.; Shiimura Y.; Nakagita T.; Tsuge K.; Yoshida S.; Kuribara T.; Hosoya T.; Sugimoto Y.; Nomura N.; Sato M.; Hirokawa T.; Kinoshita M.; Murata T.; Takayama K.; Yamamoto M.; Narumiya S.; Iwata S.; Kobayashi T.; Ligand binding to human prostaglandin E receptor EP at the lipid-bilayer interface. Nat Chem Biol 2019,15(1),18-26. (PMID: 10.1038/s41589-018-0131-330510193) Maeda S.; Xu J.; N Kadji F.M.; Clark M.J.; Zhao J.; Tsutsumi N.; Aoki J.; Sunahara R.K.; Inoue A.; Garcia K.C.; Kobilka B.K.; Structure and selectivity engineering of the M muscarinic receptor toxin complex. Science 2020,369(6500),161-167. (PMID: 10.1126/science.aax251732646996) Nishino T.; Okamoto K.; Kawaguchi Y.; Matsumura T.; Eger B.T.; Pai E.F.; Nishino T.; The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase. FEBS J 2015,282(16),3075-3090. (PMID: 10.1111/febs.1327725817260) Zueva I.; Dias J.; Lushchekina S.; Semenov V.; Mukhamedyarov M.; Pashirova T.; Babaev V.; Nachon F.; Petrova N.; Nurullin L.; Zakharova L.; Ilyin V.; Masson P.; Petrov K.; New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer’s disease. Neuropharmacology 2019,155,131-141. (PMID: 10.1016/j.neuropharm.2019.05.02531132435) Cunha E.S.; Chen X.; Sanz-Gaitero M.; Mills D.J.; Luecke H.; Cryo-EM structure of Helicobacter pylori urease with an inhibitor in the active site at 2.0 Å resolution. Nat Commun 2021,12(1),230. (PMID: 10.1038/s41467-020-20485-633431861) Vilar S.; Cozza G.; Moro S.; Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008,8(18),1555-1572. (PMID: 10.2174/15680260878678662419075767) Saleem U.; Shehzad A.; Shah S.; Raza Z.; Shah M.A.; Bibi S.; Chauhdary Z.; Ahmad B.; Antiparkinsonian activity of Cucurbita pepo seeds along with possible underlying mechanism. Metab Brain Dis 2021,36(6),1231-1251. (PMID: 10.1007/s11011-021-00707-633759084) Bibi S.; Hasan M.M.; Wang Y.B.; Papadakos S.P.; Yu H.; Cordycepin as a promising inhibitor of SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Curr Med Chem 2022,29(1),152-162. (PMID: 10.2174/1875533XMTE3xNDEq034420502) Daina A.; Michielin O.; Zoete V.; SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017,7(1),42717. (PMID: 10.1038/srep4271728256516) Sander T.; Freyss J.; von Korff M.; Rufener C.; DataWarrior: An open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015,55(2),460-473. (PMID: 10.1021/ci500588j25558886) Sadia S.; Khan U.; Somia G.; Zeeshan A.S.; Syed F.Z.; Mehreen L.; Evaluation of in vitro antioxidant capacity and reducing potential of polyherbal drug Entoban. Afr J Pharm Pharmacol 2015,29(40),982-987. (PMID: 10.5897/AJPP2015.4349) Khan I.U.; Carbonic anhydrase and urease inhibitory effects of Sonchus Asper. Life Sci J 2013,10(1). (PMID: 10.1055/a-1908-0935) Sweeney A.P.; Wyllie S.G.; Shalliker R.A.; Markham J.L.; Xanthine oxidase inhibitory activity of selected Australian native plants. J Ethnopharmacol 2001,75(2-3),273-277. (PMID: 10.1016/S0378-8741(01)00176-311297862) Hameed B.J.; Shari F.H.; Ramadhan U.H.; Anti-hyperuricemic, uricosuric and xanthine-oxidase inhibitory activities of Watermelon powder in a rat gout model. Pharm Biol 2010,48,1376-1383. (PMID: 10.3109/13880209.2010.48352120738177) Mendelsohn L.D.; ChemDraw 8 ultra, windows and macintosh versions. J Chem Inf Comput Sci 2004,44(6),2225-2226. (PMID: 10.1021/ci040123t) Bibi S.; Sakata K.; Current status of computer-aided drug design for type 2 diabetes. Curr Computeraided Drug Des 2016,12(2),167-177. (PMID: 10.2174/157340991266616042612070927113465) Khan M.; Patujo J.; Mushtaq I.; Ishtiaq A.; Tahir M.N.; Bibi S.; Khan M.S.; ullah N.; Mustafa G.; Mirza B.; Badshah A.; Murtaza I.; Anti-diabetic potential, crystal structure, molecular docking, DFT, and optical-electrochemical studies of new dimethyl and diethyl carbamoyl-N, N′-disubstituted based thioureas. J Mol Struct 2022,1253,132207. (PMID: 10.1016/j.molstruc.2021.132207) Catto M.; Pisani L.; Leonetti F.; Nicolotti O.; Pesce P.; Stefanachi A.; Cellamare S.; Carotti A.; Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg Med Chem 2013,21(1),146-152. (PMID: 10.1016/j.bmc.2012.10.04523199476) Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X (96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1. Adv Drug Deliv Rev 2001,46(1-3),3-26. (PMID: 10.1016/S0169-409X(00)00129-011259830) Veber D.F.; Johnson S.R.; Cheng H.Y.; Smith B.R.; Ward K.W.; Kopple K.D.; Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002,45(12),2615-2623. (PMID: 10.1021/jm020017n12036371) Stanzione F.; Giangreco I.; Cole J.C.; Use of molecular docking computational tools in drug discovery. Prog Med Chem 2021,60,273-343. (PMID: 10.1016/bs.pmch.2021.01.00434147204) Zeferino R.C.F.; Piaia V.A.A.; Orso V.T.; Pinheiro V.M.; Zanetti M.; Colpani G.L.; Padoin N.; Soares C.; Fiori M.A.; Riella H.G.; Synthesis of geranyl acetate by esterification of geraniol with acetic anhydride through heterogeneous catalysis using ion exchange resin. Chem Eng Res Des 2021,168,156-168. (PMID: 10.1016/j.cherd.2021.01.031) Andreadou I.; Schulz R.; Papapetropoulos A.; Turan B.; Ytrehus K.; Ferdinandy P.; Daiber A.; Di Lisa F.; The role of mitochondrial reactive oxygen species, NO and H S in ischaemia/reperfusion injury and cardioprotection. J Cell Mol Med 2020,24(12),6510-6522. (PMID: 10.1111/jcmm.1527932383522) Daenen K.; Andries A.; Mekahli D.; Van Schepdael A.; Jouret F.; Bammens B.; Oxidative stress in chronic kidney disease. Pediatr Nephrol 2019,34(6),975-991. (PMID: 10.1007/s00467-018-4005-430105414) Lee H.; Jose P.A.; Coordinated contribution of NADPH oxidase-and mitochondria-derived reactive oxygen species in metabolic syndrome and its implication in renal dysfunction. Front Pharmacol 2021,12,670076. (PMID: 10.3389/fphar.2021.67007634017260) Gonzalez-Vicente A.; Hong N.; Garvin J.L.; Effects of reactive oxygen species on renal tubular transport. Am J Physiol Renal Physiol 2019,317(2),F444-F455. (PMID: 10.1152/ajprenal.00604.201831215804) Wang W.; Kang P.M.; Oxidative stress and antioxidant treatments in cardiovascular diseases. Antioxidants 2020,9(12),1292. (PMID: 10.3390/antiox912129233348578) Schlickmann F.; Boeing T.; Mariano L.N.B.; da Silva R.C.M.V.A.; da Silva L.M.; de Andrade S.F.; de Souza P.; Cechinel-Filho V.; Gallic acid, a phenolic compound isolated from Mimosa bimucronata (DC) Kuntze leaves, induces diuresis and saluresis in rats. Naunyn Schmiedebergs Arch Pharmacol 2018,391(6),649-655. (PMID: 10.1007/s00210-018-1502-829663016) Pandey M.; Singh A.; Agnihotri N.; Kumar R.; Saha P.; Pandey R.P.; Kumar A.; Clinical pharmacology and therapeutic uses of diuretic agents: A review. J Res Appl Sci Biotechnol 2022,1,11-20. (PMID: 10.55544/jrasb.1.3.3) Titko T.; Perekhoda L.; Drapak I.; Tsapko Y.; Modern trends in diuretics development. Eur J Med Chem 2020,208,112855. (PMID: 10.1016/j.ejmech.2020.11285533007663) Shaito A.; Thuan D.T.B.; Phu H.T.; Nguyen T.H.D.; Hasan H.; Halabi S.; Abdelhady S.; Nasrallah G.K.; Eid A.H.; Pintus G.; Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety. Front Pharmacol 2020,11,422. (PMID: 10.3389/fphar.2020.0042232317975) van Wyk A.S.; Prinsloo G.; Health, safety and quality concerns of plant-based traditional medicines and herbal remedies. S Afr J Bot 2020,133,54-62. (PMID: 10.1016/j.sajb.2020.06.031) Alotaibi B.S.; Ijaz M.; Buabeid M.; Kharaba Z.J.; Yaseen H.S.; Murtaza G.; Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: A review. Drug Des Devel Ther 2021,15,4713-4732. (PMID: 10.2147/DDDT.S32723834848944) Sharma S.; Yaduwanshi P.S.; Sanodiya I.K.; Kumar M.; Soni M.; Dwivedi M.; A mini review on health benefits of plant-based secondary metabolites. J Pharm Negat Results 2022,2022,5389-5395. (PMID: 10.47750/pnr.2022.13.S10.655) Ellison D.H.; Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol 2019,14(8),1248-1257. (PMID: 10.2215/CJN.0963081830936153) Peirlinck M.; Costabal F.S.; Yao J.; Guccione J.M.; Tripathy S.; Wang Y.; Ozturk D.; Segars P.; Morrison T.M.; Levine S.; Kuhl E.; Precision medicine in human heart modeling. Biomech Model Mechanobiol 2021,20(3),803-831. (PMID: 10.1007/s10237-021-01421-z33580313) Pereira B.P.; do Vale G.T.; Ceron C.S.; The role of nitric oxide in renovascular hypertension: From the pathophysiology to the treatment. Naunyn Schmiedebergs Arch Pharmacol 2022,395(2),121-131. (PMID: 10.1007/s00210-021-02186-z34994823) Carlström M.; Nitric oxide signalling in kidney regulation and cardiometabolic health. Nat Rev Nephrol 2021,17(9),575-590. (PMID: 10.1038/s41581-021-00429-z34075241) Ahmad A.; Dempsey S.K.; Daneva Z.; Azam M.; Li N.; Li P.L.; Ritter J.K.; Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci 2018,19(9),2605. (PMID: 10.3390/ijms1909260530177600) Cowley A.W.; Mori T.; Mattson D.; Zou A.P.; Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003,284(6),R1355-R1369. (PMID: 10.1152/ajpregu.00701.200212736168) Savedchuk S.; Phachu D.; Shankar M.; Sparks M.A.; Harrison-Bernard L.M.; Targeting glomerular hemodynamics for kidney potection. Adv Kidney Dis Health 2023,30(2),71-84. (PMID: 10.1053/j.akdh.2022.12.00336868736) Krüger-Genge A.; Blocki A.; Franke R.P.; Jung F.; Vascular endothelial cell biology: An update. Int J Mol Sci 2019,20(18),4411. (PMID: 10.3390/ijms2018441131500313) Silva R.; Nitric oxide signaling and the cross talk with prostanoids pathways in vascular system. Med Chem 2016,13(4),5627. (PMID: 10.2174/1573406412666161228115627) Luo S.; Caveolin-1 regulates cellular metabolism: A potential therapeutic target in kidney disease. Front Pharmacol 2021,12,768100. (PMID: 10.2174/1573406412666161228115627) Zhang Y.; Liu Y.; Sun J.; Zhang W.; Guo Z.; Ma Q.; Arachidonic acid metabolism in health and disease. MedComm 2023,4(5),e363. (PMID: 10.1002/mco2.36337746665) Xavier F.E.; Nitrergic perivascular innervation in health and diseases: Focus on vascular tone regulation. Acta Physiol (Oxf) 2020,230(1),e13484. (PMID: 10.1111/apha.1348432336027) Verschuren E.H.J.; Castenmiller C.; Peters D.J.M.; Arjona F.J.; Bindels R.J.M.; Hoenderop J.G.J.; Sensing of tubular flow and renal electrolyte transport. Nat Rev Nephrol 2020,16(6),337-351. (PMID: 10.1038/s41581-020-0259-832127698) Mandal A.K.; Mount D.B.; The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015,77(1),323-345. (PMID: 10.1146/annurev-physiol-021113-17034325422986) Maiuolo J.; Oppedisano F.; Gratteri S.; Muscoli C.; Mollace V.; Regulation of uric acid metabolism and excretion. Int J Cardiol 2016,213,8-14. (PMID: 10.1016/j.ijcard.2015.08.10926316329) Jin M.; Yang F.; Yang I.; Yin Y.; Luo J.J.; Wang H.; Yang X.F.; Uric acid, hyperuricemia and vascular diseases. Front Biosci 2012,17(1),656-669. (PMID: 10.2741/395022201767) Albert D.; Scudder P.N.; Bagley P.; Saag K.G.; Vascular consequences of hyperuricemia and hypouricemia. Rheum Dis Clin North Am 2019,45(3),453-464. (PMID: 10.1016/j.rdc.2019.04.00531277755) Sachs L.; Batra K.L.; Zimmermann B.; Medical implications of hyperuricemia. Med Health R I 2009,92(11),353-355. (PMID: 19999892) Agnoletti D.; Cicero A.F.G.; Borghi C.; The impact of uric acid and hyperuricemia on cardiovascular and renal systems. Cardiol Clin 2021,39(3),365-376. (PMID: 10.1016/j.ccl.2021.04.00934247750) Zhang Y.; Jin L.; Liu J.; Wang W.; Yu H.; Li J.; Chen Q.; Wang T.; Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. J Ethnopharmacol 2018,214,29-36. (PMID: 10.1016/j.jep.2017.12.00429233733) Zhao H.; Huang J.; Miao L.; Yang Y.; Xiao Z.; Chen Q.; Huang Q.; Ai K.; Toward Urease-free wearable artificial kidney: Widened interlayer spacing MoS2 nanosheets with highly effective adsorption for uremic toxins. Chem Eng J 2022,438,135583. (PMID: 10.1016/j.cej.2022.135583) Shi C.; Zhou Z.; Chi X.; Xiu S.; Yi C.; Jiang Z.; Chen R.; Zhang L.; Liu Z.; Recent advances in gout drugs. Eur J Med Chem 2023,245(Pt 1),114890. (PMID: 10.1016/j.ejmech.2022.11489036335742) |
| Grant Information: | 83/013.186/2023 Foundation for the Support of Education, Science, and Technology Development of the State of Mato Grosso do Sul (FUNDECT, Brazil) |
| Contributed Indexing: | Keywords: Antioxidant activity; gout; hypertension; hyperuricemia; natural products; nitric oxide; xanthine oxidase. |
| Substance Nomenclature: | EC 1.17.3.2 (Xanthine Oxidase) 0 (Diuretics) 0 (Acetates) EC 3.1.1.7 (Acetylcholinesterase) EC 3.5.1.5 (Urease) |
| Entry Date(s): | Date Created: 20240905 Date Completed: 20260406 Latest Revision: 20260406 |
| Update Code: | 20260406 |
| DOI: | 10.2174/0109298673300632240823061848 |
| PMID: | 39234901 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!